Home
Scientific R&D
Research Ability
Pipeline
News Activity
News Center
News
Createrna was invited to participate in the Chinese Pharmaceutical Innovation Investment Forum
MY004567 tablets was clinically approved by FDS
The application for clinical trial of MY008211A tablet was officially accepted by the State Food and Drug Administration
MY004567 tablets was approved by the FDA US. for clinical trials implied
Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
Createrna Receives Capital Injection from Well-known Investment Institutions
Createrna Announces Phase II Clinical Results of MY008211A in Treatment-Naïve PNH Patients at ASH 2024
QR Science and Technology Donates RMB 100 Million to Huazhong University of Science and Technology for Medical Research Advancement
Createrna’s CFB Inhibitor MY008211A Tablets Granted Priority Review Designation and New Drug Application Accepted by China’s NMPA
Createrna’s MY008211A Tablets (Lanoracopan Hydrochloride) Achieve Primary Efficacy Endpoint in Phase III Trial in Complement Inhibitor-Naïve PNH Patients
Createrna Receives IND Approval for Novel Class 1 Drug QR055453D Tablets for Idiopathic Pulmonary Fibrosis (IPF)
China’s First Domestically Developed Oral CFB Inhibitor: Createrna’s Lanoracopan Hydrochloride Tablets Approved for Marketing
About Us
About Createrna
Company Introduction
Development course
Management Team
Honor and Qualification
Partner
Our Culture
Contact Us
Join Us
Careers
Recruitment